SEC Form 3 · accession 0000905718-15-000564

Celldex Therapeutics, Inc. · CLDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Sr. VP & CCO

Period of report

Jul 1, 2015

Accepted (ET)

Jul 1, 2015 · 9:10 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000744218

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock, par value $0.001 per share	holding	—	—		—	3,125	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$3.99	holding	—	—	—	—	Jun 1, 2022	Common Stock	12,500	—	D
Employee Stock Option (right to buy)^F2	$16.36	holding	—	—	—	—	Jul 1, 2023	Common Stock	20,000	—	D
Employee Stock Option (right to buy)^F3	$13.45	holding	—	—	—	—	Jun 4, 2024	Common Stock	25,000	—	D
Employee Stock Option (right to buy)^F4	$25.41	holding	—	—	—	—	Jun 10, 2025	Common Stock	75,000	—	D

F1The option became exercisable as to 25% of the shares on 6/1/2013. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 4 quarters.
F2The option became exercisable as to 25% of the shares on 7/1/2014. This option is currently vested as to 10,000 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 8 quarters.
F3The option became exercisable as to 25% of the shares on 6/4/2015. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F4The option becomes exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.

Exhibit 24.1 - Power of Attorney